Lyra Therapeutics Inc.

0.20
-0.01 (-6.54%)
At close: Mar 03, 2025, 3:59 PM
0.20
2.41%
After-hours: Mar 03, 2025, 04:56 PM EST

Lyra Therapeutics Ratios Statement

Year FY23 FY22 FY21 FY20 FY19 FY18
PE Ratio -4.16 -1.72 -1.34 -4.44 -14.91 -19.29
PEG Ratio 0.13 0.04 -0.05 -0.04 -0.49 n/a
PS Ratio 167.51 69.66 198.66 n/a n/a 93.49
PB Ratio 2.92 1.18 1.65 1.31 32.73 -1.09
P/FCF Ratio -4.06 -2.18 -1.94 -4.27 -17.18 -17.42
P/OCF Ratio -4.12 -2.19 -2.19 -4.63 -17.44 -17.52
OCF/S Ratio -40.63 -31.83 -90.6 n/a n/a -5.34
Debt / Equity Ratio 0.30 0.03 0.04 0.03 0.45 n/a
Quick Ratio 5.35 6.97 2.63 15.54 1.94 12.72
Current Ratio 5.35 6.97 2.63 15.54 1.94 12.72
Asset Turnover 0.01 0.01 0.01 n/a n/a 0.05
Interest Coverage n/a -107.45 n/a n/a n/a n/a
Return on Equity (ROE) -0.7 -0.68 -1.24 -0.3 -2.2 0.06
Return on Assets (ROA) -0.44 -0.5 -0.77 -0.27 -1.08 -0.24
Return on Capital (ROIC) -0.55 -0.59 -1.19 -0.29 -1.69 -0.31
Dividend Yield n/a n/a n/a n/a n/a n/a
Payout Ratio n/a n/a n/a n/a n/a n/a
Gross Profit Margin 100.00% 21.72% -251.23% n/a n/a 100.00%
Net Profit Margin -4.02K% -4.06K% -14.88K% n/a n/a -484.65%
Pretax Profit Margin -4.02K% -4.05K% -15.27K% n/a n/a -484.65%
Operating Profit Margin -4.31K% -4.13K% -15.3K% n/a n/a -583.52%
FCF Margin -4.13K% -3.2K% -10.25K% n/a n/a -536.74%
EBITDA Margin -4.19K% -3.96K% -14.95K% n/a n/a -576.93%